Becton, Dickinson and Company BDX
183.82
4.59
2.56%
as of 25 Sep
- Market cap
- $48.8B
- P/E
- 55.4×
Follow BDX
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Becton, Dickinson and Company (BDX) P/E ratio
As of 25 September 2026, Becton, Dickinson and Company (BDX) trades at a P/E ratio of 55.4×. Over the past ten years it has ranged from 0.0× (June 2018) to 414× (October 2018); the current reading is higher than 82% of that period. That is above the Medical Instruments & Supplies industry median of 34.2× and above the Healthcare sector median of 22.7×.
P/E ratio, daily
Annual
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 25.2× | (20.90%) |
| FY2024 | 31.9× | (21.56%) |
| FY2023 | 40.6× | 37.23% |
| FY2022 | 29.6× | 8.45% |
| FY2021 | 27.3× | (57.95%) |
| FY2020 | 64.9× | 32.45% |
| FY2019 | 49.0× | (88.16%) |
| FY2018 | 414× | 1,211.19% |
| FY2017 | 31.6× | 5.09% |
| FY2016 | 30.0× | 2.72% |
Quarterly
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 45.6× | 14.51% |
| Mar 2026 | 39.8× | 59.93% |
| Dec 2025 | 24.9× | (1.22%) |
| Sep 2025 | 25.2× | 3.64% |
| 42 more quarters | Free account |
Against its own ten years
Low 0.0×
High 414×
Ten-year median
34.6×
Current reading's percentile
82
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BAX Baxter International Inc. compare | n/m |
| SOLV Solventum Corporation compare | 10.9× |
| RMD ResMed Inc. compare | 21.3× |
| ISRG Intuitive Surgical, Inc. compare | 45.8× |
| WST West Pharmaceutical Services, Inc. compare | 47.1× |
| ALC Alcon compare | 49.2× |
| BDX Becton, Dickinson and Company | 55.4× |
| RGEN Repligen Corporation compare | 253× |
| MDLN Medline Inc. compare | — |
| Medical Instruments & Supplies industry median | 34.2× |
| Healthcare sector median | 22.7× |
| Market median | 17.9× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)
More on BDX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement